Macquarie Group
RPRX icon

Macquarie Group’s Royalty Pharma RPRX Stock Holding History

Macquarie Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Sell
41,037
-5,985
-13% -$312K 0.01% 546
2026
Q1 		$2.26M Sell
47,022
-24,903
-35% -$1.09M 0.01% 517
2025
Q4 		$2.78M Buy
71,925
+18,677
+35% +$712K 0.01% 518
2025
Q3 		$1.88M Sell
53,248
-15,921
-23% -$576K ﹤0.01% 1189
2025
Q2 		$2.49M Hold
69,169
– – ﹤0.01% 1161
2025
Q1 		$2.15M Buy
69,169
+23,021
+50% +$730K ﹤0.01% 1194
2024
Q4 		$1.18M Sell
46,148
-640
-1% -$17K ﹤0.01% 1321
2024
Q3 		$1.32M Hold
46,788
– – ﹤0.01% 1326
2024
Q2 		$1.23M Buy
46,788
+1,062
+2% +$29.4K ﹤0.01% 1337
2024
Q1 		$1.39M Hold
45,726
– – ﹤0.01% 1314
2023
Q4 		$1.28M Buy
45,726
+9,217
+25% +$253K ﹤0.01% 1326
2023
Q3 		$991K Buy
36,509
+18,304
+101% +$544K ﹤0.01% 1340
2023
Q2 		$560K Buy
18,205
+8,982
+97% +$304K ﹤0.01% 1446
2023
Q1 		$332K Hold
9,223
– – ﹤0.01% 1509
2022
Q4 		$364K Buy
9,223
+2,145
+30% +$89.5K ﹤0.01% 1550
2022
Q3 		$285K Buy
7,078
+2,447
+53% +$105K ﹤0.01% 1586
2022
Q2 		$195K Hold
4,631
– – ﹤0.01% 1719
2022
Q1 		$180K Buy
4,631
+1,930
+71% +$75.8K ﹤0.01% 1822
2021
Q4 		$107K Sell
2,701
-2,380
-47% -$92.5K ﹤0.01% 1923
2021
Q3 		$184K Hold
5,081
– – ﹤0.01% 1819
2021
Q2 		$209K Buy
5,081
+137
+3% +$5.83K ﹤0.01% 1797
2021
Q1 		$216K Buy
4,944
+2,944
+147% +$140K ﹤0.01% 1686
2020
Q4 		$100K Buy
+2,000
New +$84.9K ﹤0.01% 1874

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macquarie Group's RPRX Position: Q2 2026 in Review

Macquarie Group reduced its Royalty Pharma (RPRX) stake by 13% in Q2 2026, selling an estimated $312K and leaving 41,037 shares worth $2.3M. The position accounts for 0.01% of the portfolio, ranked #546.

Macquarie Group first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. The position peaked at $2.78M in Q4 2025. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Macquarie Group held 41,037 shares of Royalty Pharma worth $2.3M as of Q2 2026.
  • Macquarie Group sold 5,985 Royalty Pharma shares in Q2 2026, an estimated $312K.
  • Royalty Pharma made up 0.01% of Macquarie Group's portfolio in Q2 2026, its #546 holding.
  • Macquarie Group first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • Macquarie Group's Royalty Pharma position peaked at $2.78M in Q4 2025.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.